[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336000-105":59,"doc-detail-336000-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","kctd15-acts-as-an-anti-tumor-factor-in-colorectal-cancer-cells-downstream-of-the-demethylase-fto-and-the-m6a-reader-ythdf2-research-summary","KCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A reader YTHDF2 - research summary","","KCTD15 functions as an anti-tumor factor in colorectal cancer by regulating RNA and protein stability along the FTO-YTHDF2 axis. The study shows reduced KCTD15 expression in CRC tissues and demonstrates that tetracycline-induced overexpression and knockdown of KCTD15 suppress proliferation and promote apoptosis in vitro and in xenografted tumors. Increased FTO activity prevents KCTD15 mRNA degradation via m6A recognition by YTHDF2. Mechanistically, KCTD15 modulates HDAC1 and enhances acetylation and stabilization of tumor suppressor p53.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kctd15-acts-as-an-anti-tumor-factor-in-colorectal-cancer-cells-downstream-of-the-demethylase-fto-and-the-m6a-reader-ythdf2-research-summary/336000/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kctd15-acts-as-an-anti-tumor-factor-in-colorectal-cancer-cells-downstream-of-the-demethylase-fto-and-the-m6a-reader-ythdf2-research-summary/336000.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does KCTD15 play in colorectal cancer cells?","Question",{"text":112,"@type":113},"KCTD15 acts as an anti-tumor factor in CRC, showing anti-proliferative and pro-apoptotic effects when modulated experimentally in vitro and in xenograft tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is KCTD15 linked to m6A modification in CRC?",{"text":117,"@type":113},"Upregulation of the m6A eraser FTO prevents KCTD15 mRNA degradation, while decreased recognition of KCTD15 RNA by the m6A reader YTHDF2 is implicated in this regulation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does KCTD15 affect the p53 pathway?",{"text":121,"@type":113},"KCTD15 decreases HDAC1 protein expression and increases acetylation of p53 at Lys373 and Lys382, delaying p53 degradation. The regulatory effect on p53 is HDAC1-dependent.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336000,1790761429,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","communications biology Article  \n\n| \u003Cbr>[https://doi.org/10.1038/s42003-024-05880-9](https://doi.org/10.1038/s42003-024-05880-9) |  |\n| --- | --- |\n| KCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A\u003Cbr>reader YTHDF2\u003Cbr> Check for updates |  |\n| Fang-Yuan Zhang1,5, Lin Wu2,5, Tie-Ning Zhang 3  & Huan-Huan Chen 4  |  |\n| Potassium Channel Tetramerization Domain Containing 15 (KCTD15) participates in the carcinogenesis of several solid malignancies; however, its role in colorectal cancer (CRC) remains unclear. Here we ﬁnd that KCTD15 exhibits lower expression in CRC tissues as compared to paracarcinoma tissues. Tetracycline (tet)-induced overexpression and knockdown of KCTD15 conﬁrms KCTD15 as an anti-proliferative and pro-apoptotic factor in CRC both in vitro and in xenografted tumors. N6-methyladenosine (m6A) is known to affect the expression, stabilization, and degradation of RNAs with this modiﬁcation. We demonstrate that upregulation offat mass and obesity-associated protein (FTO), a classical m6A eraser, prevents KCTD15 mRNA degradation in CRC cells. Less KCTD15 RNA is recognized by m6A ‘reader’ YTH N6-Methyladenosine RNA Binding Protein F2 (YTHDF2) in FTO-overexpressed cells. Moreover, KCTD15 overexpression decreases protein expression of histone deacetylase 1 (HDAC1) but increases acetylation of critical tumor suppressor p53 at Lys373 and Lys382 . Degradation of p53 is delayed in CRC cells post-KCTD15 overexpression. We furthershowthatthe regulatory effects of KCTD15on p53are HDAC1-dependent. Collectively, we conclude that KCTD15 functions as an anti-growth factor in CRC cells, and its expression is orchestrated by the FTO-YTHDF2 axis. Enhanced p53 protein stabilization may contribute to KCTD15’s actions in CRC cells. |  |\n| Colorectal cancer (CRC) is the third most common malignancy in the world, with more than 2 million new cases and more than 1 million deaths each year1,2. These cases and deaths are related to modiﬁable risk factors, such as smoking, unhealthy diet, alcohol abuse, decreased physical activity, or being overweight3. Colonoscopy and fecal occult blood tests are the current diagnostic methods for CRC4. Multiple treatment options for CRC include surgery, radiotherapy, chemotherapy and a combination of these methods improve the survival ofCRC patients, but local recurrence, distant metastasis, and ﬁnal recurrence are still observed in many CRC patients5,6. Therefore, there is an urgent need to identify new targets for the effective treatment ofCRC. | Potassium (K+) channel tetramerization domain (KCTD) protein family contains 25 members7. These proteins commonly function as components of Cullin3 (Cul3)-dependent E3 ligases, and selectively recruit substrates for ubiquitination8,9. They are reported to be implicated in a variety of diseases, including neurodegenerative diseases and cancers7,9. KCTD15 belongs to the KCTD family and plays an inconsistent role in the carcinogenesis of different cancers. Coppola et al. demonstrated that, inpatients with HER2 positive breast cancer, KCTD15 was abnormally overexpressed in the cancerous tissues, and its knockdown inhibited the proliferation of SKBR3 cells, and further sensitized these cells todoxorubicin10. A similar tumor-promoting role of KCTD15 was also |\n\n1Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China. 2Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China. 3Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. 4Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. 5These authors contributed equally: Fang-Yuan Zhang, Lin Wu. [e-mail:](e-mail: cmuztn@vip.qq.com)[ cmuztn@vip.qq.com](e-mail: cmuztn@vip.qq.com);  \nchen891[107@sina.com](107@sina.com)  \nreported in non-solid malignancy B-cell type acute lymphoblastic leukemia by Smaldone and colleag","cbCaiga0whQNRrvn","https://ap.wps.com/l/cbCaiga0whQNRrvn","pdf",5744162,15,"English","# Background\n## Clinical need and current CRC management\n## KCTD15 and m6A pathway context\n# Methods and rationale\n## m6A sites and FTO demethylase role\n## YTHDF2-mediated RNA recognition\n# Findings\n## KCTD15 expression pattern in CRC\n## Effects of KCTD15 overexpression and knockdown\n## FTO-dependent stabilization of KCTD15 mRNA\n## HDAC1-dependent regulation of p53\n# Conclusion\n## KCTD15 as an anti-growth factor via FTO-YTHDF2 axis","[{\"question\":\"What role does KCTD15 play in colorectal cancer cells?\",\"answer\":\"KCTD15 acts as an anti-tumor factor in CRC, showing anti-proliferative and pro-apoptotic effects when modulated experimentally in vitro and in xenograft tumors.\"},{\"question\":\"How is KCTD15 linked to m6A modification in CRC?\",\"answer\":\"Upregulation of the m6A eraser FTO prevents KCTD15 mRNA degradation, while decreased recognition of KCTD15 RNA by the m6A reader YTHDF2 is implicated in this regulation.\"},{\"question\":\"How does KCTD15 affect the p53 pathway?\",\"answer\":\"KCTD15 decreases HDAC1 protein expression and increases acetylation of p53 at Lys373 and Lys382, delaying p53 degradation. The regulatory effect on p53 is HDAC1-dependent.\"}]","KCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A reader YTHDF2 - research summary | PDF",1790013102,38]